MindMedMNMD
MNMD
About: Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
Employees: 57
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
196% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $4.88M
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
68% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 34
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
6% more funds holding
Funds holding: 156 [Q3] → 166 (+10) [Q4]
3% more capital invested
Capital invested by funds: $282M [Q3] → $292M (+$9.7M) [Q4]
5.78% less ownership
Funds ownership: 60.87% [Q3] → 55.09% (-5.78%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
162%
upside
Avg. target
$30
287%
upside
High target
$55
621%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 43% 1-year accuracy 76 / 175 met price target | 621%upside $55 | Buy Reiterated | 31 Jan 2025 |
Evercore ISI Group Gavin Clark-Gartner 36% 1-year accuracy 4 / 11 met price target | 201%upside $23 | Outperform Initiated | 28 Jan 2025 |
Chardan Capital Rudy Li 33% 1-year accuracy 2 / 6 met price target | 162%upside $20 | Buy Initiated | 20 Dec 2024 |
Oppenheimer Francois Brisebois 49% 1-year accuracy 18 / 37 met price target | 162%upside $20 | Outperform Reiterated | 17 Dec 2024 |
Financial journalist opinion
Based on 4 articles about MNMD published over the past 30 days
Neutral
Business Wire
2 days ago
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wis.
Positive
The Motley Fool
1 week ago
Why Mind Medicine Stock Is Skyrocketing Today
Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m.
Neutral
Business Wire
2 weeks ago
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference: Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Date: February 12, 2025 at 9:20 AM ET Location:.
Neutral
Business Wire
3 weeks ago
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD). The Panorama study will evaluate the efficacy and safety o.
Positive
The Motley Fool
1 month ago
Why Mind Medicine Stock Is Soaring Today
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.
Positive
Zacks Investment Research
1 month ago
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
2024 was a transformational year for MNMD as it executed many important milestones.
Positive
Zacks Investment Research
2 months ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
Neutral
Business Wire
2 months ago
MindMed to Be Added to the Nasdaq Biotechnology Index
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million.
Neutral
Business Wire
2 months ago
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT v.
Neutral
Business Wire
2 months ago
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are a.
Charts implemented using Lightweight Charts™